He Xin, Yang Dongyue, Lai Lingyao, Lang Jing, Wei Kebo, Xiao Min
Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
Clin Cosmet Investig Dermatol. 2024 Mar 9;17:565-571. doi: 10.2147/CCID.S458592. eCollection 2024.
Alopecia Areata is a hair disorder influenced by factors such as genetics, immune system, and environmental triggers. The pathogenesis of this condition is still unclear, leading to unsatisfactory current treatments and causing a large number of patients to suffer from it. Janus kinase inhibitors are a new class of drugs that have emerged in recent years and are expected to be promising therapeutic tools for alopecia areata. We report five patients with varying backgrounds and severity of alopecia areata. All of them had received conventional therapy without success. Five patients took Upadacitinib at a dose of 15 mg once daily, and all of them achieved satisfactory efficacy. No adverse events were observed during the treatment of 5 patients.
斑秃是一种受遗传、免疫系统和环境触发因素等影响的毛发疾病。这种病症的发病机制仍不清楚，导致目前的治疗效果不尽人意，使大量患者深受其害。Janus激酶抑制剂是近年来出现的一类新型药物，有望成为治疗斑秃的有效工具。我们报告了5例背景和斑秃严重程度各异的患者。他们均接受过传统治疗但未获成功。5例患者每日服用一次15毫克的乌帕替尼，均取得了满意的疗效。在5例患者的治疗过程中未观察到不良事件。
